CJC-1295

CJC-1295 (without DAC), also called Modified GRF 1-29, is a tetrasubstituted analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH). The substitutions protect it from enzymatic degradation, extending its half-life to roughly 30 minutes.

CJC-1295 is the short-acting GHRH analog that asks the pituitary for a clean, natural-shaped pulse of growth hormone. It is the version most researchers pair with ipamorelin for that classic 'pulse-on-pulse' GH protocol.

Binds GHRH receptors on pituitary somatotrophs, triggering pulsatile endogenous GH release. The four amino-acid substitutions block dipeptidyl peptidase-IV cleavage without changing receptor binding, giving it a useful half-life while preserving natural pulsatility.

• •GH and IGF-1 release studies
• •Pulsatile vs sustained GH research
• •CJC-1295 + Ipamorelin synergy
• •Body composition research
• •Comparison with Sermorelin and Tesamorelin

The default 'mod GRF' in research forums. People consistently debate CJC-1295 (no DAC) vs CJC-1295 DAC: the no-DAC version is preferred when researchers want to preserve natural GH pulsatility; the DAC version is preferred for steady elevation.

“The clean, short-pulse GHRH analog.”

Almost universally stacked with Ipamorelin for the canonical 'CJC + Ipa' GH pulse. Compared to Sermorelin (shorter half-life), CJC-1295 DAC (much longer half-life), and Tesamorelin (visceral-fat focus).

CJC-1295 (Modified GRF 1-29) is a short-acting GHRH analog studied for pulsatile endogenous GH release, most often paired with Ipamorelin.